Ji Yan Biomedical Partners with YC Biotech and TMU Delegation to Advance Taiwan–Japan Collaboration in Regenerative and Precision Medicine

January 2025 — Kanagawa-ken

Ji Yan Biomedical today announced its active participation in an international biomedical delegation to Japan aimed at fostering cross-border collaboration in regenerative medicine and precision healthcare. The visit was part of a broader initiative led by Dr. Chiang Hsi-Jen, Chairman of the National Federation of Dental Associations of the Republic of China and National Policy Advisor, to promote strategic cooperation between Taiwan and Japan in innovative medical technologies.

On December 21, 2024, the Taiwan Regenerative Medicine Delegation visited the Odawara Hakone Medical Checkup Clinic, a facility recognized for its precision medicine capabilities and early cancer detection programs. The delegation included YC Biotech CEO Dr. Lin Yu-Ming, and academic representatives from Taipei Medical University’s EG Biomed team, underscoring Taiwan’s multi-sector commitment to advancing biomedical innovation.

Regenerative Innovation with UC-MSC and Exosome Platforms

At the core of this initiative is Ji Yan Biomedical’s platform in umbilical cord-derived mesenchymal stem cells (UC-MSCs) and UC-MSC-derived exosomes, which are under preclinical and early regulatory development. These research-grade products are being investigated for their potential in supporting tissue regeneration, modulating inflammatory responses, and contributing to next-generation personalized medicine.

Through an exclusive collaboration with YC Biotech, Ji Yan Biomedical aims to advance the scientific validation and potential clinical translation of these biologics. All research activities remain subject to applicable regulatory standards, including local and international guidance for stem cell and exosome technologies.

“We are honored to contribute to this dialogue between Taiwan and Japan, aligning our research capabilities with broader international goals in precision healthcare,” said Dr. Ethan Shen, CEOr of Ji Yan Biomedical.

Enabling Cross-Border Exchange in Precision Screening and Stem Cell Research

The Odawara Hakone Medical Checkup Clinic specializes in early detection and personalized screening for diseases such as colorectal, gastric, and breast cancers, with a focus on patient-centered, privacy-focused services—particularly for women’s health. The delegation explored the clinic’s integrated approach to preventive healthcare and its interest in regenerative medicine, establishing a foundation for further knowledge exchange.

The visit also served to align Taiwan’s biotechnology ecosystem—including stem cell and cancer biomarker innovation—with Japan’s advanced medical infrastructure. EG Biomed, a research group from Taipei Medical University, introduced methylation-based early cancer detection methods, while YC Biotech and Ji Yan Biomedical presented ongoing developments in cell and exosome platforms.

Building a Sustainable Biomedical Partnership Between Taiwan and Japan

This initiative reflects a growing commitment to regional collaboration in life sciences. By aligning academic research, industry expertise, and clinical innovation, the Taiwan–Japan partnership seeks to enhance early detection strategies, support regenerative research, and contribute to a broader global biomedical ecosystem.

About Ji Yan Biomedical

Ji Yan Biomedical is a biotechnology company focused on advancing cell-based and exosome-enabled therapies targeting oncology, regenerative medicine, and immunological disorders. The company collaborates with academic, clinical, and industrial partners to support translational research and responsible innovation.